What is MIRM's market cap?

$6.30B, based on the Nov 4 close of $96.97.

Does Mirum Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of MIRM is sold short?

6.7M shares, 12.9% of float, as of Oct 15, 2026.

What sector is MIRM in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · MIRMHealthcarePharmaceuticals

Mirum Pharmaceuticals, Inc. Common Stock (MIRM)

$96.97+11.42%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$87.03▲ 22.84% in range

Nov 3, 2025Low $64.10 · High $128.57Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Mirum Pharmaceuticals closed at $96.97 on Nov 4, up 11.42%, 24.6% below its 52-week closing high. Volume of 1.2M shares was 1.69× its 20-day average (above normal).

Split-adjusted performance: +22.4% over one month, -11.9% over six months, +36.9% over one year.

In the quarter ended Sep 30, 2026, revenue was $185.72M, up 39.6% from a year earlier, with a net margin of -22.0%.

Short interest was 6.7M shares at the Oct 15 settlement, down 4.6% from the prior report (12.9% of float, 7.3 days to cover).

Market cap$6.30B64.9M shares

Revenue · quarter$185.7M+39.6% YoY

Diluted EPS$-0.62−1340.0% YoY

P/E · TTM—P/S 9.4×

Net margin-22.0%Gross 81.1%

Dividend yieldNone

52-week range64.10 – 128.57−24.6% from high

Volume1.2M1.69× 20-day avg

Volatility · 60d44.1%Annualised

Short % of float12.9%7.3 days to cover

Net cash-$357.6MCash $373.7M

Next earnings—Not scheduled

Split-adjusted performance

1W +13.0%1M +22.4%3M +3.0%6M −11.9%YTD +22.8%1Y +36.9%3Y +255.9%5Y +518.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum63

Revenue growth76

Net margin55

Value (low P/E)—

Size91

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short6.7M−4.6% vs prior

Days to cover7.3Settled Oct 15

% of float12.9%

Short vol. 10d54.3%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
MIRMMirum Pharmaceuticals	$96.97	+11.42%	−11.9%	+39.6%	−22.0%	—	$6.30B
LGNDLigand Pharmaceuticals	$316.13	+0.83%	+35.9%	−31.8%	−36.2%	122.9	$6.32B	Compare
IONSIonis Pharmaceuticals	$40.15	−0.67%	−47.8%	−40.7%	−42.8%	—	$6.67B	Compare
ORKAOruka Therapeutics	$101.41	+1.87%	+45.3%	—	—	—	$6.71B	Compare
PTCTPTC Therapeutics	$68.97	+1.25%	+3.6%	+69.6%	−14.4%	—	$5.76B	Compare
AMRXAmneal Pharmaceuticals	$19.95	−1.29%	+46.5%	+9.9%	7.2%	44.2	$6.95B	Compare
MANEVeradermics, Incorporated	$136.51	+2.17%	+24.4%	—	—	—	$5.70B	Compare
AXSMAxsome Therapeutics	$137.00	−1.87%	−38.5%	+51.9%	−5.0%	—	$7.18B	Compare
COGTCogent Biosciences	$31.49	+1.38%	−12.2%	—	—	—	$5.46B	Compare

News about Mirum Pharmaceuticals

All news →

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research · Oct 27, 2026▲ Positive Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesZacks Investment Research · Oct 13, 2026▲ Positive Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDVZacks Investment Research · Sep 29, 2026▲ Positive

Quick answers

What does Mirum Pharmaceuticals do?: Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases.
What is MIRM's market cap?: $6.30B, based on the Nov 4 close of $96.97.
Does Mirum Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of MIRM is sold short?: 6.7M shares, 12.9% of float, as of Oct 15, 2026.
What sector is MIRM in?: Healthcare, in the Pharmaceuticals industry.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

HQ: Foster City, CA433 employeesListed Jul 18, 2019mirumpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology